# EDGAR Filing Document

**Accession Number:** 0001658551
**File Stem:** 0001193125-26-088117
**Filing Date:** 2026-3
**Character Count:** 17272
**Document Hash:** 7eb3f7ea5d3c39af18880252cc075561
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-088117.hdr.sgml**: 20260303

**ACCESSION NUMBER**: 0001193125-26-088117

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260303

**DATE AS OF CHANGE**: 20260303

**EFFECTIVENESS DATE**: 20260303

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Amylyx Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001658551
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 464600503
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293967
- **FILM NUMBER:** 26713843

**BUSINESS ADDRESS:**
- **STREET 1:** 55 CAMBRIDGE PARKWAY
- **STREET 2:** SUITE 6W
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 617-682-0917

**MAIL ADDRESS:**
- **STREET 1:** 55 CAMBRIDGE PARKWAY
- **STREET 2:** SUITE 6W
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**As filed with the Securities and Exchange Commission on March 3, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8**

**REGISTRATION STATEMENT** 

***Under***

***The Securities Act of 1933***

## AMYLYX PHARMACEUTICALS, INC.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **46-4600503** |
| **(State or other jurisdiction of<br>incorporation or organization)** | **(I.R.S. Employer<br>Identification No.)** |

---

**55 Cambridge Parkway, Suite 6W** 

**Cambridge, MA 02142** 

**(617) 682-0917**

**(Address, including zip code and telephone number, including area code, of Registrant's principal executive offices)** 

**Amylyx Pharmaceuticals, Inc. 2022 Stock Option and Incentive Plan** 

**Amylyx Pharmaceuticals, Inc. 2022 Employee Stock Purchase Plan** 

**(Full title of the plans)** 

**Joshua B. Cohen, Co-Chief Executive Officer** 

**Justin B. Klee, Co-Chief Executive Officer** 

**Amylyx Pharmaceuticals, Inc.** 

**55 Cambridge Parkway, Suite 6W** 

**Cambridge, MA 02142** 

**(617) 682-0917**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

**Benjamin K. Marsh, Esq.** 

**Marishka DeToy, Esq.** 

**Goodwin Procter LLP** 

**100 Northern Avenue** 

**Boston, MA 02210** 

**(617) 570-1000**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**Statement of Incorporation by Reference** 

This Registration Statement on Form S-8 is filed to register the offer and sale of (i) an additional 5,494,225 shares of the Registrant's common stock, $0.0001 par value per share (the "Common Stock"), to be issued under the Registrant's 2022 Stock Option and Incentive Plan and (ii) an additional 1,098,845 shares of Common Stock to be issued under the Registrant's 2022 Employee Stock Purchase Plan. This Registration Statement incorporates by reference the contents of the registration statements on Form S-8 (File No. [333-262125](http://www.sec.gov/Archives/edgar/data/1658551/000119312522007731/d217509ds8.htm), File No. [333-270509](http://www.sec.gov/Archives/edgar/data/1658551/000119312523069220/d481666ds8.htm), File No. [333-277274](http://www.sec.gov/Archives/edgar/data/1658551/000119312524042863/d754905ds8.htm) and File No. [333-285534](http://www.sec.gov/Archives/edgar/data/1658551/000119312525045578/d921516ds8.htm)) filed by the Registrant on January 12, 2022, March 13, 2023, February 22, 2024 and March 4, 2025, respectively.

**Part II** 

**Information Required in the Registration Statement** 

**Item 8.** **Exhibits.** <br>

See the Exhibit Index below for a list of exhibits filed as part of this registration statement on Form S-8, which Exhibit Index is incorporated herein by reference.

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| &nbsp;&nbsp;&nbsp;&nbsp;4.1 | [Fourth Amended and Restated Certificate of Incorporation of Amylyx Pharmaceuticals, Inc. (Incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 11, 2022).](http://www.sec.gov/Archives/edgar/data/1658551/000119312522006731/d273128dex31.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.2 | [Second Amended and Restated Bylaws of Amylyx Pharmaceuticals, Inc. (Incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K, filed with the Securities and Exchange Commission on January 11, 2022).](http://www.sec.gov/Archives/edgar/data/1658551/000119312522006731/d273128dex32.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.3 | [Second Amended and Restated Investors' Rights Agreement among the Registrant and certain of its stockholders, dated July 1, 2021 (Incorporated by reference to Exhibit 4.2 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-261703), filed with the Securities and Exchange Commission on December 16, 2021).](http://www.sec.gov/Archives/edgar/data/1658551/000119312521359405/d155225dex42.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;5.1\* | [Opinion of Goodwin Procter LLP.](d102493dex51.htm) |
| 23.1\* | [Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.](d102493dex231.htm) |
| 23.2\* | [Consent of Goodwin Procter LLP (included in Exhibit 5.1).](d102493dex51.htm) |
| 24.1\* | [Power of Attorney (included on signature page).](#tx102493_1) |
| 99.1 | [2022 Stock Option and Incentive Plan, and form of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to the Registrant's Registration Statement on Form S-1/A (File No. 333-261703) filed with the Securities and Exchange Commission on January 3, 2022).](http://www.sec.gov/Archives/edgar/data/1658551/000119312522000260/d155225dex102.htm) |
| 99.2 | [2022 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.3 to the Registrant's Registration Statement on Form S-1/A (File No. 333-261703) filed with the Securities and Exchange Commission on January 3, 2022).](http://www.sec.gov/Archives/edgar/data/1658551/000119312522000260/d155225dex103.htm) |
| 107\* | [Filing Fee Table.](d102493dexfilingfees.htm) |

---

\* Filed herewith.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 3<sup>rd</sup> day of March, 2026.

---

| | |
|:---|:---|
| **AMYLYX PHARMACEUTICALS, INC.** | **AMYLYX PHARMACEUTICALS, INC.** |
| By: | /s/ Joshua B. Cohen |
|  | Joshua B. Cohen<br> *Co-Chief Executive Officer and Director* |
| By: | /s/ Justin B. Klee |
|  | Justin B. Klee<br> *Co-Chief Executive Officer and Director* |

---

**POWER OF ATTORNEY AND SIGNATURES** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Joshua Cohen and Justin Klee and each of them, such person's true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for such person and in such person's name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that each of said attorney-in-fact or any substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

------

---

| | | |
|:---|:---|:---|
| **Name** | **Title** | **Date** |
| /s/ Joshua B. Cohen<br> Joshua B. Cohen | Co-Chief Executive Officer and Director (Principal Executive Officer) | March 3, 2026 |
| /s/ Justin B. Klee<br> Justin B. Klee | Co-Chief Executive Officer and Director (Principal Executive Officer) | March 3, 2026 |
| /s/ James M. Frates<br> James M. Frates | Chief Financial Officer (Principal Financial Officer and<br> Principal Accounting Officer) | March 3, 2026 |
| /s/ Karen Firestone<br> Karen Firestone | Director | March 3, 2026 |
| /s/ George Mclean Milne Jr.<br> George Mclean Milne Jr., Ph.D. | Director | March 3, 2026 |
| /s/ Paul Fonteyne<br> Paul Fonteyne, M.S., M.B.A. | Director | March 3, 2026 |
| /s/ Daphne Quimi<br> Daphne Quimi | Director | March 3, 2026 |
| /s/ Bernhardt Zeiher<br> Bernhardt Zeiher, MD | Director | March 3, 2026 |

---

## Exhibit 5.1

**Exhibit 5.1** 

March 3, 2026

Amylyx Pharmaceuticals, Inc.

55 Cambridge Parkway, Suite 6W

Cambridge, MA 02142

Re: <u>Securities Being Registered under Registration Statement on Form S-8</u>

We have acted as your counsel in connection with your filing of a Registration Statement on Form S-8 (the "Registration Statement") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), on or about the date hereof relating to an aggregate of 6,593,070 shares (the "Shares") of Common Stock, par value $0.0001 per share ("Common Stock"), of Amylyx Pharmaceuticals, Inc., a Delaware corporation (the "Company"), that may be issued pursuant to the Company's 2022 Stock Option and Incentive Plan and 2022 Employee Stock Purchase Plan (collectively, the "Plans").

We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinion set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.

For purposes of the opinion set forth below, we have assumed that, at the time Shares are issued, the total number of then unissued Shares, when added to the number of shares of Common Stock issued, subscribed for, or otherwise committed to be issued, does not exceed the number of shares of Common Stock authorized by the Company's certificate of incorporation.

The opinion set forth below is limited to the Delaware General Corporation Law.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, when delivered against payment therefor in accordance with the terms of the Plans, will be validly issued, fully paid and nonassessable.

This opinion letter and the opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 *Business Lawyer* 815 (Summer 2019).

We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

Very truly yours,

<u>/s/ GOODWIN PROCTER LLP</u> 

GOODWIN PROCTER LLP

## Exhibit 23.1

**Exhibit 23.1** 

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** 

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 3, 2026, relating to the financial statements of Amylyx Pharmaceuticals, Inc., appearing in the Annual Report on Form 10-K of Amylyx Pharmaceuticals, Inc. for the year ended December 31, 2025.

/s/ Deloitte & Touche LLP

Boston, Massachusetts

March 3, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Amylyx Pharmaceuticals, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the Amylyx Pharmaceuticals, Inc. 2022 Stock Option and Incentive Plan | Other | 5494225 | $14.64 | $80435454.00 | 0.0001381 | $11108.14 |
| 2 | Equity | Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the Amylyx Pharmaceuticals, Inc. 2022 Employee Stock Purchase Plan | Other | 1098845 | $12.444 | $13674027.18 | 0.0001381 | $1888.38 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $94109481.18  |  | $12996.52  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $12996.52  |

---

 **Offering Note** <br>

<sup>1</sup> In accordance with Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions effected without the receipt of consideration which results in an increase in the number of the registrant's outstanding shares of common stock. Represents an automatic increase to the number of shares available for issuance under the Amylyx Pharmaceuticals, Inc. 2022 Stock Option and Incentive Plan (the "2022 Plan") of 5,494,225, effective as of January 1, 2026. Shares available for issuance under the 2022 Plan were previously registered on registration statements on Form S-8 filed with the Securities and Exchange Commission on January 12, 2022 (File No. 333-262125), March 13, 2023 (File No. 333-270509), February 22, 2024 (File No. 333-277274) and March 4, 2025 (File No. 333-285534). Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act. The price per share and aggregate offering price are calculated on the basis of $14.64, the average of the high and low price of the registrant's common stock as reported on the Nasdaq Global Select Market ("Nasdaq") on February 25, 2026.

<sup>2</sup> In accordance with Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions effected without the receipt of consideration which results in an increase in the number of the registrant's outstanding shares of common stock. Represents an automatic increase to the number of shares available for issuance under the Amylyx Pharmaceuticals, Inc. 2022 Employee Stock Purchase Plan (the "2022 ESPP") of 1,098,845, effective as of January 1, 2026. Shares available for issuance under the 2022 ESPP were previously registered on registration statements on Form S-8 filed with the Securities and Exchange Commission on January 12, 2022 (File No. 333-262125), March 13, 2023 (File No. 333-270509), February 22, 2024 (File No. 333-277274) and March 4, 2025 (File No. 333-285534). Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and 457(h) of the Securities Act, and based on 85% of the average of the high and low sales price of the registrant's common stock, as reported on Nasdaq on February 25, 2026. Pursuant to the 2022 ESPP, the purchase price of the shares of common stock reserved for issuance thereunder will be 85% of the fair market value per share of common stock on the applicable offering date or on the exercise date of the applicable offering period, whichever is less.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---